Incyte $INCY pancreatic cancer drug— it targets KRAS G12D -- induces lasting tumor responses, company says at #ESMO26 https://www.statnews.com/2026/10/26/incyte-esmo-pancreatic-ca

Adam Feuerstein ✡️· @adamfeuerstein · X·2026-10-26 21:59· 2 days agoScore70

Body

Incyte $INCY pancreatic cancer drug— it targets KRAS G12D -- induces lasting tumor responses, company says at #ESMO26 https://www.statnews.com/2026/10/26/incyte-esmo-pancreatic-cancer-incb161734-results/

1202 views · 2 likes · 0 reposts · 0 replies

Conference abstracts

1039PNCT05067283 NCT05067283 NCT05067283matched by Developmental therapeutics

Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study

https://esmocongress.esmo.org

2551TIPNCT07541170 NCT07541170 NCT07541170matched by NSCLC, early stage

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

2683Pmatched by NSCLC, metastatic

First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01

https://esmocongress.esmo.org

Source: Adam Feuerstein ✡️ · x.com